GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Vaccine Biologics Corp (ROCO:6547) » Definitions » Revenue

Medigen Vaccine Biologics (ROCO:6547) Revenue : NT$605.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medigen Vaccine Biologics Revenue?

Medigen Vaccine Biologics's revenue for the three months ended in Dec. 2024 was NT$128.8 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$605.6 Mil. Medigen Vaccine Biologics's Revenue per Share for the three months ended in Dec. 2024 was NT$0.39. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$1.82.

Warning Sign:

Medigen Vaccine Biologics Corp revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Medigen Vaccine Biologics was 55.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -50.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 188.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Medigen Vaccine Biologics's highest 3-Year average Revenue per Share Growth Rate was 508.90% per year. The lowest was -50.40% per year. And the median was 207.10% per year.


Medigen Vaccine Biologics Revenue Historical Data

The historical data trend for Medigen Vaccine Biologics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Vaccine Biologics Revenue Chart

Medigen Vaccine Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.51 3,280.99 365.04 389.62 605.64

Medigen Vaccine Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.34 58.60 175.22 243.01 128.81

Competitive Comparison of Medigen Vaccine Biologics's Revenue

For the Biotechnology subindustry, Medigen Vaccine Biologics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Revenue distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Revenue falls into.


;
;

Medigen Vaccine Biologics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$605.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Vaccine Biologics  (ROCO:6547) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Medigen Vaccine Biologics Revenue Related Terms

Thank you for viewing the detailed overview of Medigen Vaccine Biologics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Vaccine Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Neihu Road, Lane 120, Floor 7, Section 1, Neihu District, Taipei, TWN, 11493
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Medigen Vaccine Biologics Headlines

No Headlines